| StockFetcher Forums · Stock Picks and Trading · Pattern Watching | << 1 ... 9 10 11 12 13 ... 20 >>Post Follow-up |
| Nobody 404 posts msg #158596 - Ignore Nobody modified |
2/15/2022 9:47:48 AM |
| Nobody 404 posts msg #158716 - Ignore Nobody modified |
3/3/2022 1:52:37 PM
Standard Lithium Ltd. explores for, develops, and processes lithium brine properties in the United States. Its flagship project is the Lanxess project with approximately 150,000 acres of brine leases located in south-western Arkansas. The company was formerly known as Patriot Petroleum Corp. and changed its name to Standard Lithium Ltd. in December 2016. Standard Lithium Ltd. was incorporated in 1998 and is headquartered in Vancouver, Canada. |
| Nobody 404 posts msg #158742 - Ignore Nobody modified |
3/6/2022 11:13:46 PM
looks like The Loch Ness Monster pattern ¯_(ツ)_/¯ |
| Nobody 404 posts msg #158775 - Ignore Nobody modified |
3/10/2022 12:03:07 PM
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California. |
| Nobody 404 posts msg #158818 - Ignore Nobody modified |
3/15/2022 11:14:39 AM
|
| Nobody 404 posts msg #158820 - Ignore Nobody modified |
3/16/2022 4:22:08 PM |
| Nobody 404 posts msg #158825 - Ignore Nobody modified |
3/18/2022 9:24:23 AM |
| Nobody 404 posts msg #158826 - Ignore Nobody modified |
3/18/2022 9:26:31 AM
ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy, work conditioning, hand therapy, aquatic therapy, functional capacity assessment, sports medicine, wellness programs, and home health. The company provides outpatient physical therapy services under the ATI Physical Therapy name. As of March 31, 2021, it had 882 owned and 22 managed clinics. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois. |
| Nobody 404 posts msg #158827 - Ignore Nobody modified |
3/18/2022 9:33:36 AMHAPPY FRIDAY EVERYONE |
| Nobody 404 posts msg #158867 - Ignore Nobody modified |
3/23/2022 3:13:11 PM |
| StockFetcher Forums · Stock Picks and Trading · Pattern Watching | << 1 ... 9 10 11 12 13 ... 20 >>Post Follow-up |